Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial

Part 1 results of the open-label, randomized, global phase 3 SPARKLE trial supported continued assessment of ibrutinib with either modified rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone (RVICI) in pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, G. A. Amos, Vinti, Luciana, Kabickova, Edita, Beishuizen, Auke, Tacyildiz, Nurdan, Uyttebroeck, Anne, Kang, Hyoung Jin, Luisi, Flavio, Minard-Colin, Véronique, Burkhardt, Birgit, Tamegnon, Monelle, Sun, Steven, Curtis, Madeliene, Deshpande, Sanjay, Nottage, Kerri, Howes, Angela, Srinivasan, Srimathi, Bhojwani, Deepa, Norris, Robin, Cairo, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984435/
https://www.ncbi.nlm.nih.gov/pubmed/36541957
http://dx.doi.org/10.1182/bloodadvances.2022008802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984435/
https://www.ncbi.nlm.nih.gov/pubmed/36541957
http://dx.doi.org/10.1182/bloodadvances.2022008802

Ejemplares similares